Risk of Major Cardiovascular and Cerebrovascular Events in Users of Lisdexamfetamine and Other Medications for Attention-Deficit/Hyperactivity Disorder in Denmark and Sweden: A Population-Based Cohort Study
ConclusionOur findings suggest little to no increased risk of cardiovascular and cerebrovascular events in patients treated with LDX compared with patients previously treated with other ADHD medications.
Source: Neurology and Therapy - Category: Neurology Source Type: research
More News: ADHD | Amphetamine | Brain | Cardiology | Cardiovascular | Concerta | Coronary Heart Disease | Denmark Health | Heart | Heart Attack | Heart Disease | Hyperactivity | Methylphenidate | Neurology | Ritalin | Strattera | Stroke | Study | Sweden Health | Vyvanse